Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, open-label, two-way crossover, single- and multiple-dose relative bioavailability study of tofacitinib extended-release (XR) and tofacitinib immediate-release (IR)

Next Previous
Trial Profile

A randomised, open-label, two-way crossover, single- and multiple-dose relative bioavailability study of tofacitinib extended-release (XR) and tofacitinib immediate-release (IR)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Atopic dermatitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 21 Mar 2016 New trial record
  • 11 Mar 2016 Results from this and other phase I study, published in the Journal of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top